Toshihide Shima

List of Publications by Citations

Source: https://exaly.com/author-pdf/4368883/toshihide-shima-publications-by-citations.pdf

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

22 972 14 23 g-index

23 1,169 5.9 3.33 ext. papers ext. citations avg, IF L-index

#	Paper	IF	Citations
22	Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2011 , 9, 428-33; quiz e50	6.9	292
21	Genetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non-alcoholic fatty liver disease in Japanese. <i>PLoS ONE</i> , 2012 , 7, e38322	3.7	194
20	Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease. <i>Journal of Gastroenterology</i> , 2011 , 46, 101-7	6.9	143
19	Risk estimation model for nonalcoholic fatty liver disease in the Japanese using multiple genetic markers. <i>PLoS ONE</i> , 2018 , 13, e0185490	3.7	57
18	The novel cutoff points for the FIB4 index categorized by age increase the diagnostic accuracy in NAFLD: a multi-center study. <i>Journal of Gastroenterology</i> , 2018 , 53, 1216-1224	6.9	37
17	A simple scoring system using type IV collagen 7S and aspartate aminotransferase for diagnosing nonalcoholic steatohepatitis and related fibrosis. <i>Journal of Gastroenterology</i> , 2018 , 53, 129-139	6.9	35
16	Hepatic senescence marker protein-30 is involved in the progression of nonalcoholic fatty liver disease. <i>Journal of Gastroenterology</i> , 2010 , 45, 426-34	6.9	29
15	Classification of patients with non-alcoholic fatty liver disease using rapid immunoassay of serum type IV collagen compared with liver histology and other fibrosis markers. <i>Hepatology Research</i> , 2017 , 47, 216-225	5.1	26
14	Identification of novel noninvasive markers for diagnosing nonalcoholic steatohepatitis and related fibrosis by data mining. <i>Hepatology</i> , 2016 , 63, 462-73	11.2	25
13	Clinicopathological features of liver injury in patients with type 2 diabetes mellitus and comparative study of histologically proven nonalcoholic fatty liver diseases with or without type 2 diabetes mellitus. <i>Journal of Gastroenterology</i> , 2013 , 48, 515-25	6.9	19
12	Influence of lifestyle-related diseases and age on the development and progression of non-alcoholic fatty liver disease. <i>Hepatology Research</i> , 2015 , 45, 548-59	5.1	19
11	Accuracy of non-invasive scoring systems for diagnosing non-alcoholic steatohepatitis-related fibrosis: Multicenter validation study. <i>Hepatology Research</i> , 2018 , 48, 1099-1107	5.1	16
10	Epidemiology: Pathogenesis, and Diagnostic Strategy of Diabetic Liver Disease in Japan. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	15
9	Hepatocellular carcinoma as a leading cause of cancer-related deaths in Japanese type 2 diabetes mellitus patients. <i>Journal of Gastroenterology</i> , 2019 , 54, 64-77	6.9	14
8	Activation of apoptosis inhibitor of macrophage is a sensitive diagnostic marker for NASH-associated hepatocellular carcinoma. <i>Journal of Gastroenterology</i> , 2018 , 53, 770-779	6.9	12
7	Assessment of transient elastography in Japanese patients with non-alcoholic fatty liver disease. <i>Hepatology Research</i> , 2017 , 47, 882-889	5.1	12
6	Diagnostic accuracy of combined biomarker measurements and vibration-controlled transient elastography (VCTE) for predicting fibrosis stage of non-alcoholic fatty liver disease. <i>Journal of Gastroenterology</i> , 2020 , 55, 100-112	6.9	9

LIST OF PUBLICATIONS

5	Early Tumor Shrinkage as a Predictive Factor for Outcomes in Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Analysis. <i>Cancers</i> , 2020 , 12,	6.6	7
4	Artificial intelligence/neural network system for the screening of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. <i>Hepatology Research</i> , 2021 , 51, 554-569	5.1	7
3	Novel artificial intelligent/neural network system for staging of nonalcoholic steatohepatitis. Hepatology Research, 2021 , 51, 1044-1057	5.1	1
2	A novel rapid immunoassay of serum type IV collagen 7S for the diagnosis of fibrosis stage of nonalcoholic fatty liver diseases. <i>Hepatology Research</i> , 2021 , 51, 263-276	5.1	1
1	Honokiol Acts as a Potent Anti-Fibrotic Agent in the Liver through Inhibition of TGF-II/SMAD Signaling and Autophagy in Hepatic Stellate Cells <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	1